StockNews.com Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Hold

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a report released on Friday morning.

Separately, HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Aclaris Therapeutics currently has an average rating of “Hold” and an average price target of $11.00.

Aclaris Therapeutics Price Performance

ACRS stock opened at $3.14 on Friday. The stock has a market capitalization of $224.29 million, a PE ratio of -6.15 and a beta of 0.10. The company’s 50-day moving average is $1.49 and its 200-day moving average is $1.30. Aclaris Therapeutics has a 1 year low of $0.77 and a 1 year high of $3.54.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The company had revenue of $4.35 million for the quarter, compared to the consensus estimate of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, analysts anticipate that Aclaris Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aclaris Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BML Capital Management LLC increased its stake in Aclaris Therapeutics by 9.7% in the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after buying an additional 1,261,866 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Aclaris Therapeutics by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock worth $6,113,000 after purchasing an additional 207,418 shares during the last quarter. Millennium Management LLC increased its stake in shares of Aclaris Therapeutics by 1.9% during the 2nd quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after purchasing an additional 63,358 shares during the last quarter. Stonepine Capital Management LLC increased its stake in shares of Aclaris Therapeutics by 27.6% during the 3rd quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock worth $2,828,000 after purchasing an additional 531,427 shares during the last quarter. Finally, Trium Capital LLP increased its stake in shares of Aclaris Therapeutics by 1.1% during the 3rd quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock worth $2,200,000 after purchasing an additional 20,940 shares during the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.